

BIONTECH

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious diseases and other indications of unmet patient need:

Oncology

Drug class	Platform	Product candidate	Indication (target)	Phase 1	Phase 1/2	Phase 2	Phase 3	Rights/Colaborator
mRNA	FixVac	BNT111	Advanced, R/R melanoma	█	█	█		Fully owned ¹
		BNT112	Metastatic/localized prostate cancer	█	█			
		BNT113	Metastatic/ R/R HPV16+ head and neck cancer	█	█	█		
		BNT116	1L metastatic NSCLC	█	█	█		
	iNeST	BNT122 (Autogene cevumeran)	1L advanced melanoma	█	█	█		Genentech ² (global 50:50 profit/loss share)
			Adjuvant colorectal cancer	█	█	█		
			Adjuvant pancreatic ductal adenocarcinoma	█	█	█		
	RiboMabs	BNT142	Multiple solid tumors	█	█			Fully owned
			Multiple solid tumors (CD3xCLDN6)	█	█			
			Multiple solid tumors (IL-2 variant)	█	█			
RiboCytokines	BNT151	Multiple solid tumors (IL-7, IL-2)	█	█			Fully owned	
	BNT152 + BNT153	Multiple solid tumors (IL-7, IL-2)	█	█				
Cell therapies	CAR T cells + CARVac	BNT211	Multiple solid tumors (CLDN6)	█	█			Fully owned
	Neoantigen-based T cells	BNT221	Refractory metastatic melanoma	█	█			Fully owned
Protein-based therapeutics	Next-generation immune checkpoint modulators	aPD(L)1-R/R metastatic NSCLC (PD-L1x4-1BB)	█	█	█		Genmab (global 50:50 profit/loss share)	
		BNT311 / GEN1046	2L Endometrial Cancer (PD-L1x4-1BB)	█	█	█		
		Multiple solid tumors (PD-L1x4-1BB)	█	█	█			
		BNT312 / GEN1042	Multiple solid tumors (CD40x4-1BB) ³	█	█	█		
		BNT313 / GEN1053	Multiple solid tumors (CD27)	█	█	█		
	BNT322 / GEN1056	Multiple solid tumors	█	█				
	Targeted cancer antibodies	BNT316 / ONC-392 (gotistobart)	aPD(L)1-R/R metastatic NSCLC (CTLA-4)	█	█	█	█	OncoC4 (exclusive global license)
			Platinum-resistant ovarian cancer (CTLA-4)	█	█	█		
			Multiple solid tumors (CTLA-4)	█	█	█		
	Antibody- drug conjugates	BNT321	Pancreatic cancer (sLea)	█	█			Fully owned
BNT323 / DB-1303		Multiple solid tumors (HER2)	█	█	█			
BNT324 / DB-1311		Multiple solid tumors	█	█	█			
BNT325 / DB-1305		Multiple solid tumors (TROP2)	█	█	█			
BNT326 / YL202	Multiple solid tumors (HER3)	█	█			Medilink Therapeutics (exclusive global license excluding Mainland China, Hong Kong SAR, Macau SAR)		
SMI ⁴	Toll-like receptor binding	BNT411	Multiple solid tumors (TLR7)	█	█			Fully owned

Infectious Diseases

Drug class	Product candidate	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	Commercial	Rights/Colaborator
mRNA	COMIRNATY (BNT162b2)	COVID-19	█	█	█	█	█	Fosun Pharma (Mainland China, Hong Kong SAR, Macau SAR, Taiwan region) Pfizer (rest of the world) ⁵
	BNT162b4 (T-cell enhancing)		█	█				
	BNT162b6/7 (Enhanced spike antigen)		█	█	█			
	BNT162b2+BNT161 ⁶		█	█				
	BNT161	Influenza	█	█	█		Partnered with Pfizer globally	
	BNT163	HSV	█	█			Exclusive license to Pfizer	
	BNT164	Tuberculosis	█	█			Collaboration with University of Pennsylvania	
	BNT165	Malaria	█	█			Collaboration with Bill & Melinda Gates Foundation ⁷	
	BNT166	Mpox	█	█			Fully owned	
	BNT167	Shingles	█	█			In partnership with CEPI ⁸	
							Partnered with Pfizer globally	

1 FixVac platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration.

2 A member of the Roche group.

3 Two Phase 1/2 clinical trials in patients with solid tumors are ongoing in combination with ICI+/- chemotherapy.

4 Small Molecule Immunomodulators.

5 BioNTech holds the commercialization license in Türkiye and Germany as part of the collaboration with Pfizer.

6 The COVID-19-Influenza combination is a Phase 1 trial in partnership with Pfizer. Further development is subject to reaching agreement.

7 BioNTech holds worldwide distribution rights except developing countries where Bill & Melinda Gates Foundation holds distribution rights.

8 Coalition for Epidemic Preparedness Innovations